Statin May Lower Risk of CV Events, Death Among HD Patients

Share this article:

VANCOUVER, B.C.—Statin treatment may decrease the risk of cardiovascular (CV) events and all-cause mortality in hemodialysis (HD) patients, according to researchers.

A post-hoc analysis of data from the AURORA trial showed that normalizing levels of high-sensitive C-reactive protein (hsCRP) and low-density lipoprotein cholesterol (LDL-C) with rosuvastatin was associated with a 47% decreased risk of major CV events, a 46% decreased risk of CV death, and a 29% decreased risk of death from any cause, investigators reported at the World Congress of Nephrology.

AURORA (A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events) was a randomized, double-blind, placebo-controlled study of patients aged 50-80 years and who had been treated with regular HD or hemofiltration for three or more months. Subjects were randomized to receive either rosuvastatin 10 mg daily or placebo, with follow-up visits at three months after randomization and then every six months. The mean duration of study treatment and follow-up was 2.4 and 3.2 years, respectively.

The post-hoc analysis, by Bengt Fellström, MD, of Uppsala University Hospital in Uppsala, Sweden, and colleagues, examined whether or not patients achieved hs-CRP levels below 2.0 mg/L and/or LDL-C levels below 67 mg/dL at three and/or 12 months following randomization. The primary endpoint was time to first major CV event (CV death, non-fatal myocardial infarction, or stroke).

Of the 2,776 patients randomized into AURORA, 813 had hsCRP levels below 2.0 mg/L after three and/or 12 months of treatment, 1,418 had LDL-C below 67 mg/dL, and 509 had both hsCRP below 2.0 mg/L and LDL-C below 67 mg/dL, Dr. Fellström's team reported.

LDL-C was not a risk factor for CV events in the study population as whole but in the 813 patients who achieved hsCRP levels below 2.0 mg/L, higher baseline LDL-C emerged as a significant risk factor for major CV events, according to the researchers. In contrast, among patients who only achieved hsCRP levels of 2.0 mg/L or higher, higher baseline LDL-C was associated with decreased risk.

Share this article:
You must be a registered member of RUN to post a comment.

Next Article in World Congress of Nephrology

Sign Up for Free e-newsletters

More in World Congress of Nephrology

Peritoneal Dialysis Cheaper than Hemodialysis Worldwide

Boosting PD use in the U.S. to 12% of dialysis patients from the current 7% would save about $300 million a year, researcher says.

Kidney Disease, Fatigue Linked

Fatigue in CKD and ESRD patients may be due to reasons other than sleep quality.

Discharge eGFR in AKI Patients Can Be Misleading

Calculations may fail to take into account the expected fall in creatinine due to loss of muscle mass.